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Abstract
Aim: Impairment in neuropsycholo-
gical functioning is common in major
depressive disorder (MDD), but it is
not clear to what degree these deficits
are related to risk (e.g. trait), scar,
burden or state effects of MDD. The
objective of this study was to use
neuropsychological measures, with
factor scores in verbal fluency, pro-
cessing speed, attention, set-shifting
and cognitive control in a unique
population of young, remitted,
unmedicated, early course individ-
uals with a history of MDD in hopes of
identifying putative trait markers of
MDD.
Methods: Youth aged 18–23 in remis-
sion from MDD (rMDD; n = 62) and
healthy controls (HC; n = 43) were
assessed with neuropsychological
tests at two time points. These were
from four domains of executive func-
tioning, consistent with previous
literature as impaired in MDD: verbal
fluency and processing speed, con-
ceptual reasoning and set-shifting,
processing speed with interference
resolution, and cognitive control.
Results: rMDD youth performed
comparably to HCs on verbal fluency
and processing speed, processing
speed with interference resolution,
and conceptual reasoning and set-
shifting, reliably over time. Individ-
uals with rMDD demonstrated
relative decrements in cognitive
control at Time 1, with greater stabil-
ity than HC participants.
Conclusion: MDD may be character-
ized by regulatory difficulties that do
not pertain specifically to active
mood state or fluctuations in symp-
toms. Deficient cognitive control may
represent a trait vulnerability or early
course scar of MDD that may prove a
viable target for secondary prevention
or early remediation.
Key words: depression, executive functioning, neuropsychology,
remission, youth.
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INTRODUCTION
Major depressive disorder (MDD) is a chronic and
disabling disorder associated with significant
impairment in functioning and high rates of relapse.
Cognitive dysfunction is one illness feature particu-
larly important for understanding course and
impairment in MDD, as it has been linked to
increased susceptibility to relapse, poor occupa-
tional functioning and reduced quality of life.1–3
Active state MDD has been consistently associated
with a wide range of cognitive deficits, including
attention,4–11 processing speed,9–13 visuospatial
abilities,4,11,14 memory4,8,9,15,16 and executive
dysfunction.4,10,17–19 Importantly, performance in
several of these neuropsychological domains may
be linked to symptom severity20 and diminished
treatment response.18,21–25 Despite broad under-
standing that cognition is reduced during depres-
sion, there is still a lack of consensus regarding the
specificity of these deficits.
Several other illness features likely contribute to
the lack of specificity, or variability in cognitive
functioning among depressed individuals26; fea-
tures that many previous MDD studies of cognition
in the active state have failed to measure. For
instance, in most studies, patient populations are
heterogeneous with respect to number or duration
of MDD episodes, severity of MDD episodes or
current symptoms, age of illness onset, length of
illness, current age, treatment and medication
status, psychiatric co-morbidity, and even primary
diagnosis.27 Relatively few studies of neuropsy-
chological functioning exist among early course
samples of adolescents or young adults.28 Further-
more, most studies of neuropsychological perfor-
mance in MDD are small, cross-sectional studies
that have compared cognitive abilities in sympto-
matic patients with those of matched controls27
offering limited power to consider many of these
MDD features outlined above. A recent meta-
analysis of 113 studies that revealed significantly
impaired performance in MDD across several
domains of executive functioning also examined the
role of potential moderating variables such as
symptom severity/remission status, age, medica-
tion and psychiatric co-morbidities.29 Some of these
variables were related to the degree of impairment
in domains of cognitive functioning (e.g. processing
speed, verbal fluency, verbal memory, shifting, inhi-
bition); however, the analysis was underpowered to
fully dissociate these effects in other domains (e.g.
visual working memory, planning, updating).
One strategy to avoid past challenges regarding
participant heterogeneity is to study a more homo-
geneous set of individuals within a more restricted
window of MDD characteristics. To optimize under-
standing of trait features of MDD, it may be advan-
tageous to study those with MDD with few episodes,
currently in remission, at a point of both develop-
mental and mood stability. This is a point in the
illness when cognitive systems are unlikely to dem-
onstrate changes associated with increasing illness
burden or state effects.30 To understand the meth-
odological advantages of studying cognition in this
epoch of MDD, it is helpful to divide illness factors
affecting cognition in depression into four broad
categories: (i) risk/trait; (ii) state; (iii) scar; and (iv)
burden (see Fig. 1). Risk/trait effects refer to charac-
teristics present prior to illness onset. State effects of
MDD include severity of symptoms, duration of
current episode, co-morbid psychiatric conditions
and treatment related to the current episode. Scar
effects are decrements in abilities and functioning
FIGURE 1. The what and when of measurement: model of depressive risk, onset and course on executive functioning. , risk; ,
state; , scar; , burden; , healthy comparison.
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after an episode, inferring a potential failure to
achieve complete inter-episode recovery. Burden
refers to the repetitive and possibly cumulative
effects of illness characteristics over time. This
framework suggests that studying cognitive func-
tioning early, in a remitted state, offers a unique
window into possible trait vulnerability factors and
early neurobiological abnormalities in depression.31
Several existing studies have assessed cognitive
functioning in the remitted state. A recent review of
adults concluded that neuropsychological deficien-
cies persist in remission relative to healthy controls
(HCs), particularly in the domains of sustained and
selective attention, memory, and executive func-
tion.32 These patients were in remission from
depression as defined by cut-off scores on clinician-
rated depression scales; however, variability in
illness features including subsyndromal symptoms,
duration of remission, chronicity and medication
status made it difficult to estimate the magnitude of
cognitive deficits observed during remission. An
additional problem with studying risk traits in MDD
is that few studies have collected repeated measure-
ments of cognitive functioning; a method that is
ideal for evaluating reliability of any impairment.
Few longitudinal studies have addressed the stabil-
ity of neuropsychological deficits over time in active
state MDD and longitudinal studies are notably
scarce in remitted MDD (for a review see 33). None of
the existing longitudinal studies reviewed were con-
ducted in youth samples (lowest mean age was 41
years16) and 14 of these studies were actually in late-
life depression, limiting the conclusions that can be
drawn about the early stages of illness. Moreover,
many are limited by variability in assessment
windows that could be overly vulnerable to practice
effects, with repeat testing ranging from 1 week34 to
1 year later.35–37 It is also worth noting that only 18 of
the 30 studies reviewed included a healthy compari-
son group.33
To address these key methodological gaps in the lit-
erature, we investigated for trait or scar risk factors
in cognitive functions among unmedicated late ado-
lescents in remission from depression with repeated
assessments. Based on previous research,29,32 we
hypothesized that executive functions (processing
speed with interference resolution, conceptual
reasoning/set-shifting, and cognitive control) would
be impaired in the rMDD group relative to HCs, and
stable over time. By contrast, we hypothesized that
verbal fluencyandprocessing speedwouldbe compa-
rable in the rMDD and HC groups and stable over
time. Positive results in this sample would indicate
that deficits in executive functions are not exclusively
due to state and chronic burden effects.
METHOD
Participants
Study participants were English-speaking young
adults between the ages of 18 and 23 with a history
of one to three episodes of MDD who are currently
in remission (rMDD; n = 62) and similarly aged HCs
(n = 43). Participants were recruited from the com-
munity surrounding two study sites: University of
Michigan (UM; n = 40) and the University of Illinois
at Chicago (UIC; n = 65).
rMDD participants met criteria for the study if
they: (i) currently scored 7 or below on the Hamilton
Depression Rating Scale, 17-item (HAM-D38); and
(ii) reported between one and three prior episodes
of MDD. rMDD participants could enroll with
current or past co-morbid anxiety disorders, but
were excluded if they met criteria for a substance
use disorder (last 2 years) or childhood onset atten-
tion deficit/hyperactivity disorder. HC participants
could not meet current or past criteria for any axis I
or axis II psychiatric disorder and could not have
any first-degree relatives with a history of psychiat-
ric illness. In addition, all enrolled participants were
free of any psychiatric medication for 90 days, did
not have head injury with loss of conscious greater
than 10 minutes, and did not suffer from any signifi-
cant birth complications or chronic medical condi-
tions that would affect cognitive functioning.
Procedure
After the initial phone screen, participants com-
pleted a diagnostic interview and clinician-rated
measures of depression. Previous MDD was estab-
lished using the Diagnostic Interview for Genetic
Studies,39 with single-blind confirmation by phone
with a parent/guardian/older sibling using a modi-
fied Family Interview for Genetic Studies.39 Depres-
sion was assessed using the HAM-D38 by a trained
interviewer. Anxiety was assessed using the Hamil-
ton Anxiety Rating Scale (HAM-A40). Following diag-
nostic confirmation, participants completed a
battery of neuropsychological assessments. This
test battery was repeated, spanning 3–15 weeks
later. Ninety-one per cent of HC participants
(n = 39) and 92% of rMDD participants (n = 57)
completed the follow-up battery.
Neuropsychological test battery
Neuropsychological tests focused heavily upon
areas known to be impaired in active state MDD,
including memory, processing speed, attention and
executive functioning. Specific tasks included the
A. T. Peters et al.
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Stroop Color and Word Test,41 the Controlled Oral
Word Association Test,42 Digit Symbol from the
Wechsler Adult Intelligence Scale-IV,43 the Trail
Making Test–Parts A and B,44 and the Parametric
Go/No-Go Task.11,45,46 The Parametric Go/No-Go
Task is a measure of cognitive control. It has
demonstrated reliability and validity in previous
studies.11,45 The task consists of three conditions or
levels that ascend in difficulty. For all three levels, a
series of sequential letters are presented rapidly on a
computer screen, and participant responses were
recorded on a designated computer keyboard key. In
the first level of the task, the ‘Go’ condition, partici-
pants respond to three target letters every time they
are presented. In levels 2 and 3, ‘Go/No-Go’ condi-
tions, the participants are expected to keep track of
the last target to which they had responded and
inhibit responding to that target until they had seen
and responded to either one or two alternate targets
(non-repeating rule), respectively.
Data analytic approach
All analyses were conducted in SPSS with an
alpha threshold of .05. Primary analyses sought to
assess differences between rMDD and HC partici-
pants on neuropsychological domains. Next, we
used factor analysis to obtain more reliable esti-
mates of underlying cognitive constructs, minimiz-
ing measurement error and consistent with prior
convention.11,47,48 Standard data reduction tech-
niques (confirmatory principal axis factor analysis
with oblique rotation) were used to reduce the tests
using conceptually and theoretically categorized
variables, consistent with our prior studies.49,50
Any scores with negative scale properties were
inverted; as a result, lower factor scores reflect
poorer performance.
Mixed-effects regression models51 (MRMs) were
conducted to examine changes in neuropsychology
functions over time, group differences between
rMDD and HC participants in performance, and
group × time interactions in performance. MRMs
are well suited for repeated measures: they are
robust to the data dependency that occurs with
repeated assessments of individuals over time.
MRMs are efficient in handling missing data by
using all available data for a given participant to
estimate group trends at each time point. Models for
each neuropsychological domain as a dependent
variable included both fixed (time, diagnosis (coded
HC = 0, rMDD = 1)) and random (patient) effects.
Cronbach’s alpha and intra-class correlation coeffi-
cients were computed to evaluate the stability of
performance over time.
RESULTS
Sample composition
Participants were an average age of 21.14 (SD 1.70),
65% female (n = 68), with approximately 14.63 years
of education (SD = 1.50). Additional descriptive sta-
tistics for demographic and clinical characteristics
of the sample are presented in Table 1. rMDD and
HC groups were of similar age, IQ, years of educa-
tion, sex distribution, racial distribution and time
between neuropsychological assessments. Partici-
pants from UIC and UM were of comparable age,
race, sex and education. Participants recruited from
UM had higher IQ (UM: M = 111.21, SD = 8.96; UIC:
M = 103.66, SD = 8.96; P < .001) and lower levels of
anxiety (UM: M = 1.31, SD = 2.01; UIC: M = 2.63,
SD = 3.40), t(50) = −2.10, P = .036.
Though in the remitted state, rMDD participants
had higher depression and anxiety rating scores
than HCs. All rMDD participants scored 7 or below
on these measures (range = 0–7); the average score
for both ratings in the rMDD group was substan-
tially lower than this cut-off. rMDD participants
were medication free for a minimum of 6 months,
70% were medication naïve. rMDD participants
were on average of 2.68 (SD = 2.94) years since the
end of the last episode. Modal number of previous
depressive episodes was 1, and 90% were never hos-
pitalized. Average age of onset was 16.53 (SD = 3.38).
TABLE 1. Clinical and demographic characteristics of rMDD and
HC participants
Variable rMDD (n = 62) HC (n = 43)
Age 20.92 (1.61) 20.73 (1.66)
Shipley Verbal IQ 106.25 (9.65) 106.73 (9.30)
Years of education 14.31 (1.38) 14.53 (1.41)
Depressive severity (HAM-D)** 2.71 (3.43) .42 (1.03)
Anxiety severity (HAM-A)** 3.20 (3.35) .65 (1.56)
Female (%) 47 (72.3) 23 (57.5)
Caucasian (%) 34 (53.1) 28 (70.0)
Days between
neuropsychological
assessments
50.79 (25.97) 55.88 (36.56)
Age of onset 16.53 (3.38)
Years since most recent
MDD episode
2.68 (2.94)
Medication naïve (%) 28 (70.0)
Never hospitalized (%) 46 (90)
Longest MDD duration (weeks) 32.23 (36.71)
*P < .05; **P < .01.
() denotes SD unless otherwise noted, percentages are calculated based on
per cent of available cases.
HC, healthy control; MDD, major depressive disorder; rMDD, remission
from MDD.
Executive function in remitted MDD
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Factor scores
The resulting factor scores included verbal fluency
and processing speed, conceptual reasoning and
set-shifting, processing speed with interference
resolution, and cognitive control. Factor loadings
are reported in Table 2.
Neuropsychological functioning
Statistical parameters for each model reported
below are presented in Table 3. rMDD participants
demonstrated domain-specific decrement in cogni-
tive control relative to HCs at Time 1. At Time 2,
performance of HCs declined (low stability in this
sample), such that the between-group performance
difference in cognitive control (stable performance)
no longer remained significant. rMDD and HC par-
ticipants demonstrated comparable performance
on verbal fluency and processing speed, processing
speed with interference resolution, and conceptual
reasoning and set-shifting. Performance on these
domains was stable over time in both groups.
Reliability
Table 4 reports the internal consistency values for
neuropsychological performance across domains
among all participants and according to diagnosis.
Alpha and intra-class correlation coefficients were
generally in the acceptable to excellent range.
Overall internal consistency was excellent for verbal
fluency and processing speed (α = .92), good for
processing speed with interference resolution
(α = .80), acceptable for conceptual reasoning and
set-shifting (α = .63) and cognitive control (α = .67).
Notably, internal consistency in the rMDD group
was higher than HCs across all domains. In particu-
lar, the rMDD deficit in cognitive control was more
reliable over time (α = .74) than cognitive control
among HCs (α = .58), which was poor.
Clinical correlates of cognitive control
Illness characteristics of rMDD, such as residual
symptoms or scar effects from prior episodes, may
contribute to the observed relative deficit in cogni-
tive control in rMDD at Time 1. Therefore, we evalu-
ated the association between the cognitive control
domain and clinical attributes specific to MDD
among the rMDD group. Residual depressive symp-
toms (HAM-D; r = −.04, P = .773.), residual anxiety
symptoms (HAM-A; r = −.08, P = .574.), number of
prior depressive episodes (r = −.06, P = .862), age at
onset (r = .07, P = .666), number of hospitalizations
(r = −.02, P = .905), longest episode duration (r = .08,
P = .631), years since last episode (r = .20, P = .219)
and being medication naïve (r = .11, P = .521) were
unrelated to the rMDD deficit in cognitive control.
DISCUSSION
In the current study, deficits in inhibitory regulatory
processes persisted during remission from depres-
sive episodes in rMDD. rMDD participants demon-
strated poorer cognitive control relative to HCs. This
is the first study to show that these cognitive control
markers were reliable and stable over time in rMDD,
and unrelated to residual depressive symptoms or
chronicity of illness. That cognitive control was
unrelated to sub-threshold symptoms or illness
burden rules out the possibility that active illness is
the sole cause of poor inhibition regulation. If defi-
cits in inhibition were associated with symptom
severity, prior illness characteristics, or vulnerable
to state fluctuations in depression, then interfer-
ence in cognitive performance could be interpreted
as temporal repercussions or concomitants of
depressive symptoms, and would be minimally
informative about underlying mechanisms or vul-
nerabilities. In contrast, deficits in cognitive control
were present independent of current severity in
rMDD, suggesting a more robust signature, or inter-
mediate phenotype, of MDD exists. This intermedi-
ate phenotype is similar to that observed in bipolar
disorder (impairment in executive functioning,
attention, memory, fine motor function52), although
the intermediate phenotype of rMDD constitutes a
more specific domain of executive functioning.
rMDD participants demonstrated more stable
performance in cognitive control relative to HCs of a
small to medium effect size. Although HCs con-
verged with rMDD on cognitive control perfor-
mance at Time 2, declining performance among
HCs over time is common with repeat performance
of neuropsychological tests and likely representa-
tive of distraction and suspect effort rather than true
abnormalities in cognitive performance.53,54 The HC
group may also be more prone to boredom in a
study with no direct or long-term benefits and only
being compensated for their time. In contrast, the
higher reliability scores of this relative deficit in
rMDD suggest the possibility that it is a more stable
and robust measure of a potential trait illness char-
acteristic. It is unclear whether the effect observed
at Time 1 translates to observable clinical impair-
ment in the real world, highlighting that
neuropsychological screenings can provide valu-
able, and potentially otherwise undetectable infor-
mation about illness characteristics that may
A. T. Peters et al.
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constitute vulnerabilities. This distinction could be
clarified in future studies by incorporating
neuropsychological assessments in a longitudinal
high-risk design to evaluate whether the same dif-
ferences are present before the first onset of MDD,
and whether the differences are related to the clini-
cal outcomes in the long term.
rMDD participants did not differ from HCs in pro-
cessing speed with interference resolution, verbal
fluency and processing speed, or conceptual rea-
soning and set-shifting. Even within the umbrella of
executive functions, relatively lower order cognitive
processes, such as sustained or divided attention,
may remain intact in the early course of MDD, and
that challenges in these areas are an artefact of
either active symptoms or chronic illness burden. In
contrast, the higher order process of responding
flexibly to new information or inhibiting prepotent
impulses in response to changing goals may
uniquely represent either an early course scar or risk
factor for MDD. In this sense, the failure of the
higher order ability to manage and direct lower
order cognitive processes or impulses may consti-
tute a vulnerability in the cognitive system that
precedes impairment in more basic processes with
prolonged persistence of depression. This possibil-
ity is consistent with a prior comprehensive review
of cognition among young adults with internalizing
disorders that suggests executive dysfunction is
present in early course MDD, but that other
domains of cognition are not consistently
impaired.55
A key strength of this study is that detection of
cognitive deficits was optimized by restricting the
sample to individuals early in their illness course
whose performance is not affected by a chronic
illness burden. However, results of this study cannot
fully dissociate whether observed differences con-
stitute trait risk for the illness, or potential early scar
effects on brain structure and function deriving
from a less than full recovery from the index
episode. An additional limitation of the study is that
although no participants were informed of the spe-
cific hypotheses of the study, rMDD participants
were aware that they were recruited based on a past
history of depression, which could have operated as
a demand characteristic or stereotype threat leading
them to perform more poorly in cognitive control. It
TABLE 3. Effects of time and diagnosis on neuropsychological factor scores in rMDD and HC
Mixed-effects regression models Effect sizes (d)
Variable b SE P Time 1 Time 2
Verbal fluency and
processing speed
Diagnosis −.07 .24 .755 .18 .03
Time −.09 .20 .653
Time × Diagnosis −.02 .12 .847
Conceptual
reasoning and set
shifting
Diagnosis −.43 .23 .063 .38 .28
Time −.17 .22 .434
Time × Diagnosis .13 .13 .301
Processing speed
with interference
resolution
Diagnosis −.23 .31 .462 .16 .11
Time −.03 .33 .928
Time × Diagnosis −.08 .19 .676
Cognitive control Diagnosis −.66 .32 .042 .38 .01
Time −.47 .31 .134
Time × Diagnosis .31 .19 .095
HC, healthy control; rMDD, remission from MDD.
TABLE 4. Internal consistency and test–retest reliability of neuropsychological domains in HC and rMDD participants
All participants Healthy controls rMDD
Alpha ICC Alpha ICC Alpha ICC
Verbal fluency and processing speed .92 .91 .90 .90 .93 .92
Conceptual reasoning and set-shifting .63 .64 .60 .60 .82 .81
Processing speed with interference resolution .80 .80 .66 .66 .86 .86
Cognitive control .67 .66 .58 .59 .74 .74
HC, healthy control; ICC, intraclass correlation coefficient; rMDD, remission from MDD.
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would be more likely, though, to have broader based
cognitive difficulties if stereotype threat were at play
in this sample. Further, although it is generally con-
sidered that executive functioning development
asymptotes between 14 and 15 and peaks around
age 18,56 brain regions that support executive func-
tions continue to consolidate and myelinate/prune
through the early to mid-20s.57–59 Thus, it is a critical
future endeavour to follow rMDD individuals in lon-
gitudinal, developmental designs to dissociate
points of impairment and whether this impairment
in cognitive control persists or resolves. Last,
despite the need for studies of cognition in depres-
sion that are not confounded by repeated episodes
or complex treatment histories, it deserves empha-
sizing that these findings cannot, at this point,
be generalized beyond a relatively high-functioning
group of young individuals early in their illness
course. Individuals outside this window may
demonstrate more severe impairments across more
domains of cognition. In addition, those who
were unable to reach remission by our strict criteria
may have been more likely to exhibit cognitive
difficulties.
Nonetheless, our findings have important impli-
cations for the pathoaetiology of MDD. Active state
MDD is characterized by altered inhibition-related
activity most prominently in the rostral anterior
cingulate cortex (ACC) and the dorsal lateral
prefrontal cortex (dlPFC).60 The ACC is thought to
play an essential role in shifting flexibly between
cognitive tasks and response sets, whereas the
lateral structures of the dlPFC are recruited when
competing responses need to be inhibited.61,62 These
regions operate within a cognitive control network
that maintains goals by flexibly adjusting attention
and working memory to changing environments
and demands.63 Indeed, increased activity in these
areas has been linked with successful inhibition
trials on a Go/No-Go Task,18 suggesting potential
compensatory mechanisms, and with impairment
on interference resolution tasks such as the Stroop
or continuous performance tasks.64,65 Thus, the
direction of inhibition-related activity may differ
depending on the particular nature of the task, or
potentially clinical confounds such as depressive
severity and chronicity.66 Evaluating the circuitry
involved in regulatory deficits among early course,
remitted individuals may help clarify the nature of
these abnormalities by reducing confounds of
active illness, complex treatment histories or neural
scarring resulting from decades of illness.
These findings have important clinical implica-
tions. Patterns of inflexible, maladaptive and rumi-
native thinking styles common in depression may
be related, in part, to decreased attentional
resources and cognitive control.67 Advances in
neurobehavioural training strategies, such as
computer-based cognitive control exercises, to
recruit the networks and resources necessary for
executive control via repeated behavioural exer-
cises, suggest that it is possible to strengthen cogni-
tive and emotional functions. Actively depressed
participants who have received cognitive control
training exhibited reduced negative affect and rumi-
nation, and improved concentration.68 Given that
cognitive control deficits persist in remission of
MDD, the application of cognitive control training
during the euthymic phase may prove useful in
reducing vulnerability to MDD relapse and warrant
future study.
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